Siegfried Acquires Hameln Pharma
News Dec 12, 2014
Siegfried Group will acquire the Hameln Pharma in Germany, consisting of Hameln Pharmaceuticals GmbH and Hameln RDS GmbH, with effect from end November 2014. Hameln Pharma is active in the development and production of sterile liquid pharmaceutical products for international pharma companies; the Siegfried Group will therefore considerably strengthen its sterile filling segment.
The acquired companies are located in the city of Hameln in the vicinity of Hanover in Germany and employ a workforce of approximately 500. Under terms of the acquisition agreement, Siegfried will take over the entire staff.
To date Hameln Pharma was a part of the privately held Hameln Group. For 2014, Hameln Pharma expects sales of approx. CHF 85 million. The purchase price amounts to CHF 60 million.
The Hameln Group with its remaining subsidiaries will in future focus on their worldwide business activities with their own brand of injectable pharmaceutical finished products. The research and development site in Slovakia will also remain in the possession of the Group.
Hameln Pharma is an attractive complement for Siegfried
Hameln Pharma was founded in 1950 and goes back to the “Raths-Apotheke” in Hameln, family-owned since 1890. The company began focusing on the production of parenteral products in 1970. It produces sterile liquid drugs filled in ampoules or vials for international pharmaceutical companies.
The focus of its activities is on the production of demanding compounds, such as anesthetics. To supplement its core business of contract manufacturing, Hameln Pharma offers a portfolio of accompanying services ranging from product and method development to dossier compilation and registration services.
Siegfried CEO Rudolf Hanko: “The family-owned company looks back on a history of more than 100 years and, from both a technical and a cultural point of view, represents a perfect fit with the Siegfried Group, which celebrated its 140th anniversary last year. The new location significantly supplements our activities in the field of sterile filling.
Our industry is in an intensifying consolidation process. Siegfried wants to and will play an active role in this.”
Planned expansion of activities
Hameln Pharma’s production plant is very modern. In 2008, Hameln Pharma´s new sterile facility was put into operation, which in 2009 has been awarded the internationally renowned “Facility of the Year Award” in the category Operational Excellence. Thanks to the sterile facility, the combined company now has at its disposal an innovative, efficient and flexible production plant capable of producing sterile drugs under conditions for the entire world. In the future, Siegfried will continue to invest in these technologies at both of its sites - Irvine and Hameln - and in the coming years move forward especially the production of vials in Hameln.
Another significant strategy project
With this acquisition, Siegfried has implemented its Transform strategy regarding both forward and backward integration. In 2012, Siegfried acquired Alliance Medical Products, Inc. in Irvine, California, active in a comparable market segment as Hameln Pharma.
In October 2014, operating approval was granted for the new chemical production plant for active pharmaceutical ingredients in Nantong, China. This Siegfried site has a chemical-pharmaceutical capacity of over 300 cubic meters. At its headquarters in Zofingen, Switzerland, Siegfried is currently building a chemical production plant with a capacity of 100 cubic meters which from mid-2015 will replace older and less efficient facilities.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE